Dermata Therapeutics, Inc.(DRMA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
DRMA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Dermata Therapeutics, Inc. (DRMA), a Healthcare sector company. DRMA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Dermata Therapeutics, Inc. reports net income of $-1.8M, free cash flow of $-2.5M. Top institutional holders of DRMA by reported 13-F value include GEODE CAPITAL MANAGEMENT,, UBS Group AG, WELCH & FORBES, based on the most recent SEC filings. DRMA trades on the Nasdaq exchange and files with the SEC under CIK 1853816. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DRMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Dermata Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-1.8M
Free Cash Flow
Q1 2026
$-2.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+38.5% YoYOperating Income
+37.9% YoYEPS (Diluted)
-143.8% YoYTotal Assets
+122.5% YoYTotal Debt
Op. Cash Flow
+30.1% YoY| Metric | FY 2025 | FY 2024 | FY 2021 | FY 2019 |
|---|---|---|---|---|
| Net Income | $-7.6M +38.5% | $-12.3M -55.5% | $-7.9M | — |
| Operating Income | $-7.8M +37.9% | $-12.5M -59.3% | $-7.9M | — |
| EPS (Diluted) | $-8.16 -143.8% | $-3.35 | — | — |
| Total Assets | $7.9M +122.5% | $3.5M -69.6% | $11.6M | — |
| Total Debt | — | — | $0.00 | — |
| Operating Cash Flow | $-7.8M +30.1% | $-11.2M -96.1% | $-5.7M | — |
AI Insight: DRMA Financial Trends
Pre-revenue biotech stabilizing losses and cash burn, though equity base remains volatile and underfunded.
• Net and operating losses contracted from $3M (Q2–Q4 2024) to $2M (Q1 2025 onward), a 33% improvement.
• Operating cash burn moderated to $1M in Q4 2025, best quarterly result across 9-quarter span.
• Equity base oscillated between $2M–$7M; no debt recorded throughout observation period.
⚠ Still pre-revenue after 9 quarters; no commercial traction evident. Equity volatility suggests ongoing capital raises.
⚠ Q1 2026 cash burn rebounded to $2M after Q4 2025 improvement; sustainability unclear.
AI Insight: DRMA Ratio Trends
Dermata remains deeply unprofitable with ROE deteriorating to -115.3% in Q1 2026, showing no signs of operational inflection.
• ROE worsened from -126.2% in Q1 2025 to -115.3% in Q1 2026, suggesting equity base erosion or continued net losses.
• ROA marginally improved from -92.1% in Q1 2025 to -99.0% in Q1 2026, though remains severely negative across all available periods.
⚠ ROE spiked to -170.9% in Q3 2025, the worst quarterly result on record — investigate one-time charges or capital events.
⚠ All operating/profitability metrics remain unmeasured (dashes); inability to disclose margins suggests ongoing pre-revenue or severe operational challenges.
Get alerted when DRMA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Dermata Therapeutics, Inc. including:
Top Institutional Holders of DRMA
GEODE CAPITAL MANAGEMENT, LLC
$58.5K48,334 shUBS Group AG
$43.1K35,608 shWELCH & FORBES LLC
$24.2K20,000 shBOOTHBAY FUND MANAGEMENT, LLC
$14.5K12,000 shMCF Advisors LLC
$2.1K1,732 shTower Research Capital LLC (TRC)
$866.00716 shSBI Securities Co., Ltd.
$122.00101 shUBS Group AG
$20.001,304 shCITIGROUP INC
$1.001 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $58.5K | 48,334 |
| UBS Group AG | $43.1K | 35,608 |
| WELCH & FORBES LLC | $24.2K | 20,000 |
| BOOTHBAY FUND MANAGEMENT, LLC | $14.5K | 12,000 |
| MCF Advisors LLC | $2.1K | 1,732 |
| Tower Research Capital LLC (TRC) | $866.00 | 716 |
| SBI Securities Co., Ltd. | $122.00 | 101 |
| UBS Group AG | $20.00 | 1,304 |
| CITIGROUP INC | $1.00 | 1 |
More Healthcare Companies
View all Healthcare →Put DRMA on your watchlist
Track score changes the day Dermata Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DRMA a good stock to buy?
13F Pro's AI-powered analysis of Dermata Therapeutics, Inc. (DRMA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DRMA are available on the DRMA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own DRMA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DRMA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Dermata Therapeutics, Inc.'s investment landscape.